Biodesix Raises 2026 Revenue Forecast Amid Profitability Goals
ArchivedSingle Source|3 articles|1 sources|1 blocks
Detected: Updated: Analyzed:
Reported Facts
Observable data points shared across all narratives
- •Biodesix raised its 2026 revenue outlook to a range of $108 million to $114 million.
- •The company is targeting sustained adjusted EBITDA profitability in 2026.
- •Twist Bioscience projects full-year 2026 revenue between $442 million and $447 million with a goal of adjusted EBITDA breakeven in Q4 2026.
- •Krystal Biotech plans non-GAAP operating expenses of $175 million to $195 million in 2026 and aims for six data readouts before year-end.
What Could Happen If...
- ▸Biodesix achieves sustained adjusted EBITDA profitability in 2026 the company could strengthen its financial stability and attract more investor interest, benefiting shareholders and supporting future growth.
Market Exposure
StocksBiodesix Inc.Upward Pressure
The raised revenue outlook and focus on sustained adjusted EBITDA profitability may boost investor confidence and increase demand for Biodesix shares.
This is not investment advice. Market exposure is based on conditional event analysis.
Source Coverage
FINANCE
3 articles
Signals
Single-block coverage
Related Events
▸Evolv Technology raises 2026 revenue guidance to $178MArchived▸Emergent BioSolutions sets $720M–$760M revenue target for 2026Archived▸RxSight projects $120M–$135M revenue for 2026 with commercial pushArchived▸Syndax Reports 50% Revenue Growth and Profit Plan in Q4 2025Archived▸Axsome Reports 57% Q1 Revenue Growth, Eyes $18B Peak Sales
Primary Sources (3)
FINANCESeeking Alpha - Market NewsBiodesix raises 2026 revenue outlook to $108M-$114M as it targets sustained adjusted EBITDA profitabilityFINANCESeeking Alpha - Market NewsTwist Bioscience targets $442M-$447M FY2026 revenue while staying on track for Q4 FY2026 adjusted EBITDA breakevenFINANCESeeking Alpha - Market NewsKrystal Biotech outlines $175M-$195M 2026 non-GAAP opex while targeting 6 data readouts before year-end